Results 91 to 100 of about 197,589 (314)

Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas [PDF]

open access: yes, 2005
INTRODUCTION: ScFv(FRP5)-ETA is a recombinant antibody toxin with binding specificity for ErbB2 (HER2). It consists of an N-terminal single-chain antibody fragment (scFv), genetically linked to truncated Pseudomonas exotoxin A (ETA).
Wels, Winfried   +44 more
core   +1 more source

Chromosomal Instability Drives Glioblastoma Heterogeneity and Therapeutic Opportunities

open access: yesAdvanced Science, EarlyView.
ABSTRACT Glioblastoma, the most aggressive and lethal form of brain cancer, is defined by profound genomic instability, with Chromosomal Instability (CIN) playing a central role in driving tumor progression, therapy resistance, and poor prognosis. CIN is characterized by numerical and structural alterations, is driven by mechanisms such as mitotic ...
Amarnath Pal   +3 more
wiley   +1 more source

Activation of ERBB4 Pathway Inhibits Pathological Transdifferentiation of Lung Epithelial Progenitors into CD66c+ Basal Cells in Severe Lung Injury

open access: yesAdvanced Science, EarlyView.
In fibrotic distal lung regions, CD66c+ basal cells emerge as a pathological state. Using human distal lung organoids, this study identifies CD66c+ basal cells as a pro‐fibrotic state arising through transdifferentiation from secretory, AT2, and basal cells.
Kaijun Lin   +13 more
wiley   +1 more source

Time‐Multiplexed Organic Electrochemical Transistor for Saliva‐Based Rapid Detection of Viral Proteins

open access: yesAdvanced Science, EarlyView.
A time‐multiplexed nanobody‐functionalized organic electrochemical transistor enables rapid and sensitive detection of three respiratory viral proteins from saliva. Sequentially addressed multi‐gate electrodes on a shared channel achieve around 1 fm detection within 15 min without sample preprocessing. Clinical validation demonstrates high specificity,
Tianrui Chang   +13 more
wiley   +1 more source

Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition

open access: yesOncoImmunology, 2017
Expression of human epidermal growth factor family member 3 (HER3), a critical heterodimerization partner with EGFR and HER2, promotes more aggressive biology in breast and other epithelial malignancies.
Takuya Osada   +12 more
doaj   +1 more source

Characterizing individual anti-Her2 modules and the bi-modular anti-Her2-dCK fusion proteins.

open access: yes, 2016
(A) Schematic of the ELISA assay used to evaluate the binding of the affinity reagents to the ectodomain IV of the Her2 receptor. (B) Binding of reagents to the ectodomain IV of Her2 receptor was measured by incubating 50 nM of reagents with 20 nM of ...
Arnon Lavie (307968)   +3 more
core   +1 more source

Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer [PDF]

open access: yes, 2010
In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance.
Bauerfeind, Ingo   +2 more
core   +1 more source

Covalent Inhibition of SHMT2 by Gambogic Acid Induces Ferroptosis Through Mitochondrial Collapse in Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
In this study, chemoproteomics combined with genetic and functional analyses was integrated to identify SHMT2 as a covalent and functional target of gambogic acid (GA) in triple‐negative breast cancer (TNBC). Further validation demonstrated that GA selectively modifies the Cys241 site of SHMT2, triggering mitochondrial dysfunction, activating the Nrf2 ...
Tong Yang   +15 more
wiley   +1 more source

NRG1 Fusions in NSCLC: Being eNRGy Conscious

open access: yesLung Cancer: Targets and Therapy
Brinda Gupta, Laura Gosa Barrett, Stephen V Liu Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USACorrespondence: Stephen V Liu, Georgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington,
Gupta B, Gosa Barrett L, Liu SV
doaj  

HER2-low and ultralow breast cancer: interobserver challenges and lessons from a consensus study [PDF]

open access: yesJournal of Pathology and Translational Medicine
Background The recent approval of trastuzumab deruxtecan for human epidermal growth factor receptor 2 (HER2)–low and HER2-ultralow breast cancer mandates an adequate assessment of these categories.
Jiwon Koh   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy